CRISPR Therapeutics AG (CRSP) Cash from Operations (2015 - 2026)

CRISPR Therapeutics AG has disclosed Cash from Operations across 12 years of filings, most recently posting -$83.5 million for Q2 2026.

• In Q2 2026, Cash from Operations rose 26.68% year-over-year to -$83.5 million; the TTM figure through Jun 2026 stood at -$369.6 million (down 13.8% YoY), while the FY2025 annual figure was -$345.0 million, down 141.65% from the prior year.
• Cash from Operations came in at -$83.5 million for Q2 2026 at CRISPR Therapeutics AG, up from -$108.9 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $109.8 million in Q1 2024 to a low of -$142.0 million in Q2 2022.
• Average Cash from Operations over 5 years is -$79.8 million, with a median of -$95.8 million recorded in 2023.
• The largest YoY upside for Cash from Operations was 1147.32% in 2024 against a maximum downside of 168.25% in 2024.
• Over 5 years, Cash from Operations stood at -$113.3 million in 2022, then advanced by 15.23% to -$96.1 million in 2023, then jumped by 47.92% to -$50.0 million in 2024, then tumbled by 84.99% to -$92.6 million in 2025, then grew by 9.78% to -$83.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$83.5 million in Q2 2026, -$108.9 million in Q1 2026, and -$92.6 million in Q4 2025.